Profil
Ray Takigiku is the founder of Bexion Pharmaceuticals, Inc., which was founded in 2006.
He currently holds the position of Chief Scientific Officer at Bexion Pharmaceuticals, Inc. Additionally, Dr. Takigiku is currently working as a Director at Sidis Corp.
Aktive Positionen von Ray Takigiku
| Unternehmen | Position | Beginn |
|---|---|---|
Bexion Pharmaceuticals, Inc.
 Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Gründer | 01.01.2006 |
Sidis Corp
 Sidis Corp Financial ConglomeratesFinance Sidis Corp provides investment services for market-leading life science companies. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Bexion Pharmaceuticals, Inc.
Bexion Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bexion Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of oncology treatments. The firm is developing BXQ-350, a first-in-class agent composed of the multifunctional, lysosomal activator protein Saposin C and phosphatidylserine. The company was founded by Ray Takigiku in 2006 and is headquartered in Covington, KY. | Commercial Services |
Sidis Corp
Sidis Corp Financial ConglomeratesFinance Sidis Corp provides investment services for market-leading life science companies. | Finance |
